Latest total current liabilities for SYMQY: $2.2B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
SymBio Pharmaceuticals Limited (SYMQY) currently reports a total current liabilities of $2.2B as of September 2026. That compares with $590M in the prior-year period — up 277.7% year over year. Use the charts on this page to explore SymBio Pharmaceuticals Limited's total current liabilities history and peer comparisons.
SymBio Pharmaceuticals Limited's total current liabilities increased from $590M to $2.2B — a 277.7% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
SymBio Pharmaceuticals Limited reported $2.2B in total current liabilities as of September 2026. That compares with $590M in the prior-year period — up 277.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $2.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SymBio Pharmaceuticals Limited, and consider following SYMQY for alerts when major investors trade the stock.